Overview:
WT-1 (Wilms Tumor 1 Immunohistochemistry) TestIntroduction: The WT-1 (Wilms Tumor 1 Immunohistochemistry) Test is a diagnostic tool designed to detect Wilms Tumor 1 protein expression in tissue preserved in formalin-fixed paraffin-embedded (FFPE) blocks, facilitating the diagnosis of kidney or ovarian cancer. Associated with Wilms tumor or ovarian carcinoma, these oncologic conditions present with swelling, pain, and severe complications like metastasis if untreated, particularly in children or individuals with genetic predisposition. Per the 2023 National Comprehensive Cancer Network guidelines, the test employs immunohistochemistry techniques, delivering detailed protein identification over 1-2 days with high sensitivity and specificity, making it a valuable tool for definitive diagnosis in immunohistochemistry settings. This diagnostic falls under cancer screening and targets individuals with abdominal or pelvic symptoms, addressing the challenge of accurate protein classification to guide surgical resection or chemotherapy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating treatment, and reducing complications. Its tissue-based approach ensures reliable detection.
Other Names: WT-1 IHC Test.
FDA Status: FDA approved, CLIA certified for immunohistochemistry, compliant with 2025 standards.
Historical Milestone: Introduced in the 1990s by various pathology labs, this test advanced oncology diagnostics by standardizing WT-1 detection.
Purpose: The test detects Wilms Tumor 1 protein expression to guide kidney or ovarian cancer diagnosis, assess oncologic status, and inform treatment and prevention strategies.
Test Parameters: Presence of Wilms Tumor 1 protein expression, detected with high specificity to indicate cancerous activity, typically observable in kidney or ovarian tissue at altered patterns during active disease, with protein distribution and staining intensity assessed to determine severity and distribution, providing a comprehensive profile of tumor damage that correlates with clinical presentation and guides therapeutic decisions, ensuring a detailed evaluation of affected areas.
Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report swelling, pain, or recent tumor development.
Specimen: Tissue 0.5-2 cma³, collected as FFPE, transported indefinitely to maintain sample viability.
Sample Stability at Room Temperature: Indefinite with proper paraffin embedding to preserve tissue integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: Not refrigerated, as FFPE blocks are stable at room temperature with proper storage.
Sample Stability at Frozen: Not recommended, as freezing may disrupt tissue structure, increasing the risk of false negatives and compromising diagnostic accuracy.
Medical History: Patients should provide details on swelling, pain, prior cancer, or family history of oncologic disease, as well as any recent trauma or treatments.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated cancer including metastasis, benefits of early detection, and minimal discomfort from sample collection.
Procedural Considerations: The test involves sectioning FFPE blocks, applying immunohistochemistry with anti-WT-1 antibodies, and analysis under microscopy by trained pathologists to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store blocks according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays in processing, improper fixation, cross-contamination with other samples, or recent therapy can affect results. Correlation with imaging or clinical evaluation is recommended to confirm findings.
Clinical Significance: A positive result indicates possible kidney or ovarian cancer, necessitating further investigation like ultrasound or oncology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during early stages.
Specialist Consultation: Oncologists or urologists/gynecologists should be consulted for case management, treatment planning, and coordination with cancer programs.
Additional Supporting Tests: Ultrasound, biopsy review, or CA-125 testing for confirmation.
Test Limitations: The test may produce false positives in reactive conditions or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.
References: NCCN Guidelines 2023, Journal of Pathology 2024, Immunohistochemistry 2025.
